articleThe Lancet OncologyFeb 6, 2014Closed access

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

GAGrant A. McArthurPBPaul B. ChapmanCRCaroline RobertJLJames LarkinJBJohn B.A.G. Haanen

Peter MacCallum Cancer Centre · Memorial Sloan Kettering Cancer Center · +26 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

977
total citations
FWCI
68.44
Percentile
100%
References
28
Citations per year

Authors

28

Topics & keywords

Topics
Keywords
  • Vemurafenib
  • Dacarbazine
  • Medicine
  • Internal medicine
  • Melanoma
  • Population
  • Oncology
  • Progression-free survival
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding